RTOG 94-06: Is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

International Journal of Radiation Oncology Biology Physics

Volumn 57, Issue 3, 2003, Pages 614-620

  Valicenti, Richard K ^a,h   Winter, Kathryn ^b   Cox, James D ^c   Sandler, Howard M ^d   Bosch, Walter ^e   Vijayakumar, Srinivasan ^g   Michalski, Jeff ^f   Purdy, James ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e WASHINGTON UNIVERSITY   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

3D conformal radiation therapy; Hormonal therapy; Prostate cancer; Toxicity

Indexed keywords

HORMONES; RADIOTHERAPY; TUMORS;

HORMONAL THERAPY (HT);

ONCOLOGY;

ANTIANDROGEN; GONADORELIN AGONIST;

ADULT; AGED; ARTICLE; BLADDER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSIMETRY; HIGH RISK POPULATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; RADIATION DOSE; RADIATION INJURY; RISK ASSESSMENT; SAFETY; SEMINAL VESICLE; STRATIFICATION; TUMOR VOLUME; URINARY TRACT FUNCTION; UROGENITAL TRACT DISEASE;

EID: 0141615701     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00640-0     Document Type: Article

References (26)

1. Hanks G.E., Hanlon A.L., Pinover W.H., Horwitz E.M., Price R.A., Schultheiss T. Dose selection for prostate cancer patients based on dose comparison and dose response studies. Int J Radiat Oncol Biol Phys. 46:(4):2000;823-832.
2. Hanks G.E., Martz K.L., Diamond J.J. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys. 15:1988;1299-1305.
3. Perez C.A., Pilepich M.V., Zivnuska F. Tumor control in definitive irradiation of localized carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 12:1986;523-531.
4. Valicenti R.K., Lu J., Pilepich M., et al. Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Oncology Therapy Group. J Clin Oncol. 18:2000;2740-2746.
5. Pollack A., Zagars G.K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
6. Zelefsky M.J., Leibel S.A., Gaudin P.B., et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
7. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 94-06. Int J Radiat Oncol Biol Phys. 46:(2):2000;3891-4002.
8. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 94-06 level III (79.2 Gy). Int J Radiat Oncol Biol Phys. 54:(4):2002;1036-1046.
9. Pilepich M.V., Winter K., John M.J., et al. Phase III Radiation Therapy Oncology Group (RTOG) Trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 50:2001;1243-1252.
10. Laverdiere J., Gomez J.L., Cusan L., et al. Beneficial effect of combination therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
11. Zelefsky M.J., Leibel S.A., Burman C.M., et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 29:1994;755-761.
12. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of adjuvant androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Oncology Therapy Group protocol 85-31 . J Clin Oncol. 15:1997;1013-1021.
13. Granfors T., Modig H., Damber J.E., et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement A prospective randomized study . J Urol. 159:1998;2020-2034.
14. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer. N Engl J Med. 341:1999;1781-1788.
15. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC Study) A phase III randomized trial . Lancet. 260:2002;103-108.
16. Hanks G.E., Lu J.D., Machtay M., et al. RTOG Protocol 92-02 A phase III trial of the use of long-term total androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate . Int J Radiat Oncol Biol Phys. 18:(Suppl. 1):2000;112.
17. Nakashima J., Imai Y., Tachibana M., et al. Effects of endocrine therapy on the primary lesion in patients with prostate carcinoma as evaluated by endorectal magnetic resonance imaging. Cancer. 80:1997;237-241.
18. Lim J.D., Hasegawa M., Sikes C., et al. Supra-additive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. 38:1997;1071-1078.
19. AJCC. AJCC cancer staging manual. 4th ed. Philadelphia: Lippincott-Raven; 1992.
20. ICRU 50. Report 50. Prescribing, recording, and reporting photon beam therapy. Bethesda, MD: International Commission on Radiation Units and Measurement: 1993.
21. Michalski J.M., Winter K., Purdy J.A., et al. Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 94-06 dose levels I and II. Int J Radiat Oncol Biol Phys. 56:2002;192-198.
22. Roach M. Equations for predicting the pathologic stage of men with localized prostate cancer using the preoperative prostate specific antigen (PSA) and Gleason score. J Urol. 150:1993;1923-1924.
23. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 18:(23):2000;3904-3911.
24. Chen C.T., Valicenti R.K., Lu J.D., et al. Does hormonal therapy influence sexual function in men receiving 3D conformal radiation therapy for prostate cancer? Int J Radiat Oncol Biol Phys. 50:2001;591-595.
25. Sanguineti G., Agostinelle S., Foppiano F., et al. Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma. Br J Cancer. 86:2002;1843-1847.
26. Terk M.D., Stock R.G., Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol. 160:1998;1379-1382.